Wound complications are a predictor of worse oncologic outcome in extremity soft tissue sarcomas.


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 05 10 2019
revised: 19 01 2020
accepted: 14 02 2020
entrez: 21 6 2020
pubmed: 21 6 2020
medline: 27 4 2021
Statut: ppublish

Résumé

In various oncological conditions, complications correlate with diminished prognosis, however literature on soft tissue sarcomas is limited and inconclusive. The aim of this study was to assess risk factors and the oncologic impact of wound complications in primary extremity soft-tissue sarcomas. Patients with primary extremity soft tissue sarcomas without dissemination and with clear surgical margins (R0) were analyzed. Groups with and without wound complications were compared by univariate and multivariable analysis to identify risk factors. Uni- and multivariable analysis of factors associated with local recurrence free survival (LRFS), metastasis free survival (MFS) and disease specific survival (DSS) were performed. 682 patients were included in the study, wound complications occurred in 94 patients (13.7%) within 90 days. Age, ASA-stage, high tumor size and grade, tumor location in the foot, neoadjuvant radiation therapy and operation time represented independent risk factors for wound complications. Patients with wound complications had a significantly worse estimated 5-year LRFS of 49.4 ± 6% versus 78.3 ± 2.1% and 5-year DSS of 77.9 ± 5.4% versus 89.1 ± 1.6%. Wound complications could be identified as an independent risk factor for worse LRFS (HR 2.68[CI 1.83-3.93], p < 0.001) and DSS (HR 1.79[CI 1.01-3.16], p = 0.046). Wound complications after soft tissue sarcomas of the extremities are associated with worse local oncological outcome and survival. Patients with high risk of wound complications should be identified and strategies implemented to reduce surgical complications and possibly improve oncologic prognosis.

Sections du résumé

BACKGROUND BACKGROUND
In various oncological conditions, complications correlate with diminished prognosis, however literature on soft tissue sarcomas is limited and inconclusive. The aim of this study was to assess risk factors and the oncologic impact of wound complications in primary extremity soft-tissue sarcomas.
METHODS METHODS
Patients with primary extremity soft tissue sarcomas without dissemination and with clear surgical margins (R0) were analyzed. Groups with and without wound complications were compared by univariate and multivariable analysis to identify risk factors. Uni- and multivariable analysis of factors associated with local recurrence free survival (LRFS), metastasis free survival (MFS) and disease specific survival (DSS) were performed.
RESULTS RESULTS
682 patients were included in the study, wound complications occurred in 94 patients (13.7%) within 90 days. Age, ASA-stage, high tumor size and grade, tumor location in the foot, neoadjuvant radiation therapy and operation time represented independent risk factors for wound complications. Patients with wound complications had a significantly worse estimated 5-year LRFS of 49.4 ± 6% versus 78.3 ± 2.1% and 5-year DSS of 77.9 ± 5.4% versus 89.1 ± 1.6%. Wound complications could be identified as an independent risk factor for worse LRFS (HR 2.68[CI 1.83-3.93], p < 0.001) and DSS (HR 1.79[CI 1.01-3.16], p = 0.046).
CONCLUSION CONCLUSIONS
Wound complications after soft tissue sarcomas of the extremities are associated with worse local oncological outcome and survival. Patients with high risk of wound complications should be identified and strategies implemented to reduce surgical complications and possibly improve oncologic prognosis.

Identifiants

pubmed: 32561077
pii: S0960-7404(19)30497-9
doi: 10.1016/j.suronc.2020.02.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-134

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing of interest The author(s) received no specific funding for this work and declare not conflict of interest.

Auteurs

Mehran Dadras (M)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany. Electronic address: mehran.dadras@rub.de.

Pascal Koepp (P)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany.

Christoph Wallner (C)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany.

Johannes M Wagner (JM)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany.

Alexander Sogorski (A)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany.

Marcus Lehnhardt (M)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany.

Kamran Harati (K)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany.

Björn Behr (B)

BG University Hospital Bergmannsheil, Department of Plastic Surgery, Bochum, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH